neoclarityn
n.v. organon - desloratadinas - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistamininiai vaistai sisteminio naudojimo, - neoclarityn yra nurodytas atleidimo iš simptomų, susijusių su:alerginė rhinitisurticaria.
budesonide ferring
ferring gmbh - budezonidas - pailginto atpalaidavimo tabletės - 9 mg - budesonide
trimmer® 50 sg
adama - vandenyje tirpios granules - tribenuron metilas - herbicidai
grivix
zakłady farmaceutyczne polpharma s.a. - dimetindeno maleatas - gelis - 1 mg/g; 1 g - dimetindene
legacy® pro
adama - koncentruota suspensija - chlorotoluronas + diflufenikanas + pendimetalinas - herbicidai
combirepel™ cr8181, combirepel™.
e.p.r.d., 227 rue waassertrap, l-4408, belvo, liuksemburgas - lavandos aliejus; lavandos aliejus; lavandos aliejus - veikliosios medžiagos cas nr.: 8000-28-0, eb nr.: 289-995-2, veikliosios medžiagos pavadinimas: lavandos aliejus, koncentracija: 5% , veiklioji; veikliosios medžiagos cas nr.: 8000-28-0, eb nr.: 289-995-2, veikliosios medžiagos pavadinimas: lavandos aliejus, koncentracija: 5% , veiklioji; veikliosios medžiagos cas nr.: 8000-28-0, eb nr.: 289-995-2, veikliosios medžiagos pavadinimas: lavandos aliejus, koncentracija: 5% , veiklioji - repelentai ir atraktantai
termirepel™ tr0207, termirepel™
e.p.r.d., 227 rue waassertrap, l-4408, belvo, liuksemburgas - lavandos aliejus; lavandos aliejus; lavandos aliejus - veikliosios medžiagos cas nr.: 8000-28-0, eb nr.: 289-995-2, veikliosios medžiagos pavadinimas: lavandos aliejus, koncentracija: 4% , veiklioji; veikliosios medžiagos cas nr.: 8000-28-0, eb nr.: 289-995-2, veikliosios medžiagos pavadinimas: lavandos aliejus, koncentracija: 4% , veiklioji; veikliosios medžiagos cas nr.: 8000-28-0, eb nr.: 289-995-2, veikliosios medžiagos pavadinimas: lavandos aliejus, koncentracija: 4% , veiklioji - repelentai ir atraktantai
combirepel™ cr8181, combirepel™.
e.p.r.d., 227 rue waassertrap, l-4408, belvo, liuksemburgas - lavandos aliejus; lavandos aliejus; lavandos aliejus - veikliosios medžiagos cas nr.: 8000-28-0, eb nr.: 289-995-2, veikliosios medžiagos pavadinimas: lavandos aliejus, koncentracija: 5% , veiklioji; veikliosios medžiagos cas nr.: 8000-28-0, eb nr.: 289-995-2, veikliosios medžiagos pavadinimas: lavandos aliejus, koncentracija: 5% , veiklioji; veikliosios medžiagos cas nr.: 8000-28-0, eb nr.: 289-995-2, veikliosios medžiagos pavadinimas: lavandos aliejus, koncentracija: 5% , veiklioji - repelentai ir atraktantai
termirepel™ tr0207, termirepel™
e.p.r.d., 227 rue waassertrap, l-4408, belvo, liuksemburgas - lavandos aliejus; lavandos aliejus; lavandos aliejus - veikliosios medžiagos cas nr.: 8000-28-0, eb nr.: 289-995-2, veikliosios medžiagos pavadinimas: lavandos aliejus, koncentracija: 4% , veiklioji; veikliosios medžiagos cas nr.: 8000-28-0, eb nr.: 289-995-2, veikliosios medžiagos pavadinimas: lavandos aliejus, koncentracija: 4% , veiklioji; veikliosios medžiagos cas nr.: 8000-28-0, eb nr.: 289-995-2, veikliosios medžiagos pavadinimas: lavandos aliejus, koncentracija: 4% , veiklioji - repelentai ir atraktantai
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcinos - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.